Delivery Order SPE2DB22D3010-SPE2DB25FP3FQ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) valued at $7,563.09. The contract is a firm fixed-price delivery order with an ultimate completion date of July 10, 2025, following the award date of July 9, 2025. This award was made without set-aside designation, indicating competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, fulfills the delivery at its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,111.08 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (quantity 100) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,896.36 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100-count units) under a firm fixed-price contract. The award was made on September 12, 2025, with an ultimate completion date of September 15, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,258.69 on August 18, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This non-competitive, firm fixed-price delivery order is scheduled for completion by August 19, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $5,051.16. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion by August 6, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.67 to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100 count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order, issued with no set-aside designation, is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader contracting...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,918.73. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3FQDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,351.34 to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100 count) under a firm fixed price contract. The award was made on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside provisions, reflecting the contractor's established capability to meet federal pharmaceutical procurement requirements. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. The IDC enables the company to supply a broad range of pharmaceutical products, including brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems. Vyvanse, a controlled substance used in the treatment of attention deficit hyperactivity disorder, represents one of the specialized medications within AmerisourceBergen's federal pharmaceutical portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 8/18/25 |